This review summarises the OASIS-5 trial: comparison of fondaparinux and enoxaparin in acute coronary syndromes. Despite being an older study, it is still significant and has become increasingly important with changes to current practice making it worth highlighting again.
A total of 20,000 patients were included in the trial across 576 centres. and independent commentary is provided by Professor David Brieger, an Interventional Cardiologist and Head of the Coronary Care and Coronary Interventions at Concord Repatriation General Hospital and Professor of Cardiology, Faculty of Medicine, University of Sydney.
Please login below to download this issue (PDF)